Quince

BODEN AGENCY CELEBRATES 15 YEARS OF IMPACT - ITS QUINCEAÑERA - WITH A SERVICE OFFERING EXPANSION AND BRAND REFRESH

Retrieved on: 
Tuesday, November 7, 2023
Gen, Sport, Food, Into, Generation Z, Generation Alpha, Empowerment, Growth, Pulse, Ad Age, Music, Culture, Quince, Beauty, Bottled water

MIAMI, Nov. 7, 2023 /PRNewswire/ -- Today, BODEN, an independent, minority- and female-owned, award-winning communications agency, named a three-time 2023 "Agency of the Year'' by AdAge, the Hispanic Public Relations Association and PRNews, celebrates its 15th anniversary – it's quinceañera – with a service offering expansion and brand refresh. Adding to its core service of helping brands activate campaigns that reach the Hispanic market, the agency launches Hispanic+™, a service offering that helps brands leverage the power of the Hispanic market to transcend to mainstream audiences. This 15th anniversary marks a critical milestone for BODEN, which builds on its award-winning success to date and celebrates what the agency has become – a communications powerhouse rooted in Hispanic culture.

Key Points: 
  • This 15th anniversary marks a critical milestone for BODEN, which builds on its award-winning success to date and celebrates what the agency has become – a communications powerhouse rooted in Hispanic culture.
  • The future is Hispanic and brands that tap into the significance of our culture are capturing audiences everywhere.
  • "The future is Hispanic and brands that tap into the significance of our culture are capturing audiences everywhere.
  • We have anticipated this expansion since I founded the agency 15 years ago, always embodying, as an agency, the transformative force of diversity shaping the U.S.", says Natalie Boden, CEO and Founder, BODEN.

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Retrieved on: 
Monday, October 23, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, European Investment Bank, A-T, FDA, Ageing, Therapy, Neurodegenerative disease, Acquisition, DSP, AIDE, Disease, Clinical trial, Biology, NDA, Safety, SPA, Patient, EIB, Pharmaceutical industry, Quince

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.
  • Currently, there are no approved treatments for A-T and the market represents a $1+ billion estimated peak sales opportunity globally.
  • “The successful closing of the EryDel acquisition is an exciting step forward in fulfilling our vision to build a leading rare disease biotechnology company,” said Dirk Thye, M.D., Quince’s Chief Executive Officer.
  • The acquisition of EryDel was completed with no upfront cash payment, using a stock-for-stock exchange and potential downstream milestone cash payments.

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Retrieved on: 
Thursday, September 28, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, A-T, Plastic, Therapy, New Drug Application, Clinical trial, NDA, Acquisition, Patient, Agency, SPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Quince

Currently, there are no approved treatments for patients with A-T and the market represents a $1+ billion estimated peak sales opportunity.

Key Points: 
  • Currently, there are no approved treatments for patients with A-T and the market represents a $1+ billion estimated peak sales opportunity.
  • Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “We are pleased with the FDA’s decision to lift the partial clinical hold related to EryDel’s lead asset, EryDex.
  • We look forward to completing the clinical and regulatory activities necessary to advance EryDex into the Phase 3 NEAT study – with patient enrollment beginning as soon as the second quarter of 2024.
  • The commercial version of the EryKit treatment consumables is already approved for clinical trial use in Europe.

Quince Imaging Acquires Red Envelope Consulting and Appoints Ron Birkla to Lead New Division

Retrieved on: 
Monday, September 11, 2023
CMH, PHL, Airport, QI, Multimedia, Transport, Consultant, JFK, Peggy Quince, LED, Acquisition, Lake States Transportation Division, AV, SCN, ALB, Television, Building, Quince, D.C

STERLING, Va., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Quince Imaging, a pioneer in immersive displays, announces the inauguration of its new Critical Infrastructure and Transportation Division. This strategic expansion is led by the acquisition of Red Envelope Consulting and appointing industry veteran, Ron Birkla, who brings over three decades of unparalleled experience in the AV domain.

Key Points: 
  • STERLING, Va., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Quince Imaging, a pioneer in immersive displays, announces the inauguration of its new Critical Infrastructure and Transportation Division.
  • This strategic expansion is led by the acquisition of Red Envelope Consulting and appointing industry veteran, Ron Birkla, who brings over three decades of unparalleled experience in the AV domain.
  • "Quince is thrilled to drive the transport and infrastructure market with unique LED & projection setups.
  • As part of Quince Imaging's vision to stay at the forefront of immersive visual technologies consistently, we're thrilled to reveal our recent key hires: Larry Howard, Lauren Roth, and Ron Birkla.

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Retrieved on: 
Wednesday, September 6, 2023
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Archives of Oral Biology, DSM-IV codes, Patent, A-T, College, Therapy, Western New England University, Senior, New York State Bar Association, Stony Brook University, Research, IP, CNS, Acquisition, AbbVie, Forest Laboratories, Patient, Pathology, Forest, College of Wooster, Pharmaceutical industry, Quince, Chemistry

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.
  • Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “Charles is a valuable addition to our management team.
  • His considerable expertise will help enhance efficiency and effectiveness across our research programs and business operations.
  • Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions.

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Retrieved on: 
Monday, July 24, 2023
Health, Medical Devices, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, News, EU4, A-T, Therapy, AIDE, Bank statement, Clifford Chance, Clinical trial, NDA, Toxicity, DSM-IV codes, Quality, Dexamethasone, EMA, Cooley LLP, QOL, Acquisition, EQ-5D, HIV disease progression rates, Patient, Investment, Vineland Adaptive Behavior Scale, Quality of life, SPA, Steroid, Growth, Ageing, MAA, European Investment Bank, FDA, EIB, ITT, Deficit spending, Enzyme replacement therapy, OLE, International Cooperative Ataxia Rating Scale, Safety, Korea International Cooperation Agency, Pharmaceutical industry, Cryptocurrency, Medical imaging, Quince

EryDel has developed an autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex, targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.

Key Points: 
  • EryDel has developed an autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex, targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.
  • Commercial version of EryKit treatment consumables approved in Europe and currently under partial clinical hold pending response to FDA query.
  • A-T population estimated to be approximately 10,000 patients in the U.S., U.K., and EU4 countries with no currently approved therapies and $1+ billion estimated peak sales opportunity globally.
  • MTS Health Partners, L.P. is serving as financial advisor and Cooley LLP is serving as legal counsel to Quince.

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

Retrieved on: 
Tuesday, April 11, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Therapy, Pharmaceutical industry, Quince

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash.
  • Following careful review and evaluation, the Quince Board concluded that Echo Lake Capital’s proposal undervalues the company and is not in the best interest of Quince and its shareholders.

Quince Shares Affordable Luxury on National TV

Retrieved on: 
Monday, April 10, 2023
Luxury, TV and Radio, Men, Home Goods, Family, Social Media, Consumer, Entertainment, Other Communications, Marketing, Fashion, Advertising, Communications, Retail, Other Consumer, Women, Online Retail, Social media, Multimedia, Quince

View the full release here: https://www.businesswire.com/news/home/20230410005063/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230410005063/en/
    Quince specializes in high-end, luxury clothing, accessories and home goods, but at affordable prices.
  • The brand had focused heavily on channels like social media and was interested in how a national TV campaign could attract consumers it wasn’t currently reaching.
  • "Quince was created to challenge the idea that quality should be a luxury,” says Toti Moreland, Head of Brand at Quince.
  • “We’re thrilled to be a part of bringing the brand to national TV, and we can’t wait to see how the campaign helps promote their truly beautiful products.”

Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

Retrieved on: 
Thursday, April 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Consulting, Professional Services, Clinical Trials, MTS, Disclosure, Acquisition, Therapy, Comment, Risk management, Quince

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that it has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support Quince’s Board of Directors and management team in the review and evaluation of strategic alternatives intended to maximize long-term value for all Quince stockholders.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that it has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support Quince’s Board of Directors and management team in the review and evaluation of strategic alternatives intended to maximize long-term value for all Quince stockholders.
  • The engagement will focus on the company’s previously stated prioritization of in-licensing and acquisition activities, as well as alternative options and proposals, as warranted.
  • David Lamond, Quince’s chairperson, said, “Quince is at an important juncture and has a diverse range of strategic options before it.
  • Quince does not intend to comment further until the process has concluded or the company has otherwise determined that further disclosure is appropriate or required.

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Retrieved on: 
Wednesday, April 5, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Therapy, Cyprus Securities and Exchange Commission, Shareholder rights plan, Acquisition, Holding company, Security (finance), Quince

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince’s common stock.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince’s common stock.
  • The Board adopted the Rights Plan following an unsolicited acquisition proposal and accumulation of Quince shares by certain investors.
  • A Rights Plan will enable Quince’s Board and its management team to protect stockholders while fulfilling its fiduciary responsibilities to review and evaluate strategic alternatives intended to maximize long-term value for all Quince stockholders.
  • The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Quince.